A tiny start-up company in Irvine has a shot at becoming the first to gain federal approval to test an embryonic stem cell treatment in humans.

Two degenerative nerve diseases are the first targets for California Stem Cell Inc.’s therapies. They are ALS, or Lou Gehrig’s Disease, which kills adults, and SMA, a fatal disease affecting newborns. The company hopes to win Food and Drug Administration approval next year to begin clinical trials for both sets of patients.
Read the full article here at OC register.com.